Systemic soluble receptor for advanced glycation endproducts is a biomarker of emphysema and associated with AGER genetic variants in patients with chronic obstructive pulmonary disease.

PubWeight™: 1.79‹?› | Rank: Top 3%

🔗 View Article (PMID 23947473)

Published in Am J Respir Crit Care Med on October 15, 2013

Authors

Donavan T Cheng1, Deog Kyeom Kim, Debra A Cockayne, Anton Belousov, Hans Bitter, Michael H Cho, Annelyse Duvoix, Lisa D Edwards, David A Lomas, Bruce E Miller, Niki Reynaert, Ruth Tal-Singer, Emiel F M Wouters, Alvar Agustí, Leonardo M Fabbri, Alex Rames, Sudha Visvanathan, Stephen I Rennard, Paul Jones, Harsukh Parmar, William MacNee, Gerhard Wolff, Edwin K Silverman, Ruth J Mayer, Sreekumar G Pillai, TESRA and ECLIPSE Investigators

Author Affiliations

1: 1 Hoffmann-La Roche Inc., Nutley, New Jersey.

Associated clinical trials:

Evaluation of COPD (Chronic Obstructive Pulmonary Disease) to Longitudinally Identify Predictive Surrogate Endpoints (ECLIPSE) | NCT00292552

Articles citing this

Genome-wide study of percent emphysema on computed tomography in the general population. The Multi-Ethnic Study of Atherosclerosis Lung/SNP Health Association Resource Study. Am J Respir Crit Care Med (2014) 1.80

Biomarkers of progression of chronic obstructive pulmonary disease (COPD). J Thorac Dis (2014) 1.14

A Genome-Wide Association Study of Emphysema and Airway Quantitative Imaging Phenotypes. Am J Respir Crit Care Med (2015) 1.02

Soluble receptor for advanced glycation end-products and progression of airway disease. BMC Pulm Med (2014) 0.89

The association of plasma biomarkers with computed tomography-assessed emphysema phenotypes. Respir Res (2014) 0.88

Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD. Respir Res (2014) 0.87

New developments in the assessment of COPD: early diagnosis is key. Int J Chron Obstruct Pulmon Dis (2014) 0.86

Emerging Targets for Therapeutic Development in Diabetes and Its Complications: The RAGE Signaling Pathway. Clin Pharmacol Ther (2015) 0.85

Intercellular adhesion molecule 1 and progression of percent emphysema: the MESA Lung Study. Respir Med (2014) 0.82

Genetics of Plasma Soluble Receptor for Advanced Glycation End-Products and Cardiovascular Outcomes in a Community-based Population: Results from the Atherosclerosis Risk in Communities Study. PLoS One (2015) 0.82

Association of polymorphisms of the receptor for advanced glycation end products gene with COPD in the Chinese population. DNA Cell Biol (2014) 0.80

Identifying a gene expression signature of frequent COPD exacerbations in peripheral blood using network methods. BMC Med Genomics (2015) 0.80

Epigenetic Inheritance and Its Role in Evolutionary Biology: Re-Evaluation and New Perspectives. Biology (Basel) (2016) 0.80

Candidate genes for COPD: current evidence and research. Int J Chron Obstruct Pulmon Dis (2015) 0.78

The multiple faces of RAGE - opportunities for therapeutic intervention in aging and chronic disease. Expert Opin Ther Targets (2015) 0.78

Common Genetic Polymorphisms Influence Blood Biomarker Measurements in COPD. PLoS Genet (2016) 0.77

Receptor for advanced glycation end products and soluble receptor for advanced glycation end products: a balancing act in chronic obstructive pulmonary disease? Am J Respir Crit Care Med (2013) 0.77

Local and systemic RAGE axis changes in pulmonary hypertension: CTEPH and iPAH. PLoS One (2014) 0.77

Advanced glycation endproducts and their receptor in different body compartments in COPD. Respir Res (2016) 0.77

Challenges and Current Efforts in the Development of Biomarkers for Chronic Inflammatory and Remodeling Conditions of the Lungs. Biomark Insights (2016) 0.76

Increased S100A4 expression in the vasculature of human COPD lungs and murine model of smoke-induced emphysema. Respir Res (2015) 0.76

Associations of autophagy with lung diffusion capacity and oxygen saturation in severe COPD: effects of particulate air pollution. Int J Chron Obstruct Pulmon Dis (2016) 0.75

Functional interactors of three genome-wide association study genes are differentially expressed in severe chronic obstructive pulmonary disease lung tissue. Sci Rep (2017) 0.75

The Ser82 RAGE Variant Affects Lung Function and Serum RAGE in Smokers and sRAGE Production In Vitro. PLoS One (2016) 0.75

Effect of RAGE gene polymorphisms and circulating sRAGE levels on susceptibility to gastric cancer: a case-control study. Cancer Cell Int (2017) 0.75

Bipartite Community Structure of eQTLs. PLoS Comput Biol (2016) 0.75

Protocol for a human in vivo model of acute cigarette smoke inhalation challenge in smokers with COPD: monitoring the nasal and systemic immune response using a network biology approach. BMJ Open (2015) 0.75

Receptor for advanced glycation end-products and World Trade Center particulate induced lung function loss: A case-cohort study and murine model of acute particulate exposure. PLoS One (2017) 0.75

Subtyping Chronic Obstructive Pulmonary Disease Using Peripheral Blood Proteomics. Chronic Obstr Pulm Dis (2017) 0.75

A Pilot Study Linking Endothelial Injury in Lungs and Kidneys in COPD. Am J Respir Crit Care Med (2017) 0.75

Articles by these authors

Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96

Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 10.97

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA (2006) 10.54

Meta-analysis and imputation refines the association of 15q25 with smoking quantity. Nat Genet (2010) 8.55

Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med (2011) 7.92

Genetic epidemiology of COPD (COPDGene) study design. COPD (2010) 7.67

High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med (2005) 7.20

The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08

A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet (2009) 6.93

Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med (2014) 6.29

Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med (2011) 5.69

Family-based tests for associating haplotypes with general phenotype data: application to asthma genetics. Genet Epidemiol (2004) 5.57

Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med (2012) 5.54

Genomic screening and replication using the same data set in family-based association testing. Nat Genet (2005) 5.44

Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med (2007) 5.31

Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet (2006) 5.19

Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res (2010) 5.17

Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature (2011) 4.92

Lung volumes and emphysema in smokers with interstitial lung abnormalities. N Engl J Med (2011) 4.75

Diesel exhaust inhalation causes vascular dysfunction and impaired endogenous fibrinolysis. Circulation (2005) 4.71

PBAT: tools for family-based association studies. Am J Hum Genet (2004) 4.68

An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med (2013) 4.49

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet (2009) 4.29

Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19

Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med (2015) 4.16

Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med (2006) 4.11

Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med (2005) 4.06

GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98

MMP12, lung function, and COPD in high-risk populations. N Engl J Med (2009) 3.96

Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet (2009) 3.93

An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2010) 3.92

Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest (2010) 3.91

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet (2009) 3.90

Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med (2007) 3.81

A genome-wide association study of pulmonary function measures in the Framingham Heart Study. PLoS Genet (2009) 3.78

Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 3.70

Systemic effects of smoking. Chest (2007) 3.63

Living and dying with severe chronic obstructive pulmonary disease: multi-perspective longitudinal qualitative study. BMJ (2011) 3.61

Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med (2011) 3.58

Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2013) 3.54

A multivariate family-based association test using generalized estimating equations: FBAT-GEE. Biostatistics (2003) 3.52

Variants in FAM13A are associated with chronic obstructive pulmonary disease. Nat Genet (2010) 3.44

Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med (2012) 3.44

Genome-wide association analysis identifies PDE4D as an asthma-susceptibility gene. Am J Hum Genet (2009) 3.41

Selection criteria for residency: results of a national program directors survey. Acad Med (2009) 3.41

What is chronic obstructive pulmonary disease anyway?: Continua, categories, cut points, and moving beyond spirometry. Am J Respir Crit Care Med (2013) 3.39

On the replication of genetic associations: timing can be everything! Am J Hum Genet (2008) 3.32

A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum (2007) 3.32

Chronic obstructive pulmonary disease exacerbations in the COPDGene study: associated radiologic phenotypes. Radiology (2011) 3.30

COPD guidelines: the important thing is not to stop questioning. Am J Respir Crit Care Med (2007) 3.29

Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest (2004) 3.25

Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol (2010) 3.12

Combustion-derived nanoparticles: a review of their toxicology following inhalation exposure. Part Fibre Toxicol (2005) 3.12

Adverse cardiovascular effects of air pollution. Nat Clin Pract Cardiovasc Med (2008) 3.00

The SERPINE2 gene is associated with chronic obstructive pulmonary disease in two large populations. Am J Respir Crit Care Med (2007) 2.91

Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest (2003) 2.90

FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J (2013) 2.87

Reversible cigarette smoke extract-induced DNA damage in human lung fibroblasts. Am J Respir Cell Mol Biol (2004) 2.82

Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med (2010) 2.80

Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med (2004) 2.62